The evolving paradigm of tissue-specific metastasis by DiMeo, Theresa A & Kuperwasser, Charlotte
Page 1 of 3
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/8/1/301
Introduction
Breast cancer frequently metastasizes to bone, lung, liver,
and brain, which is the major cause of morbidity and mortality
associated with the disease [1]. The propensity with which
breast cancer associates with certain tissue types in
advanced stages of malignancy suggests a molecular basis
for this attraction, but the mechanism remains unknown.
Previous dogma suggested a genetic basis for breast cancer
metastasis as an extension of the stepwise transformation
model, whereby the accumulation of genetic mutations
confers selective survival and proliferative advantages to
reach a malignant state of growth. Indeed, it was thought that
several additional genetic alterations after initial trans-
formation were required to confer metastatic ability [2].
Recent evidence has challenged this notion by suggesting
that the genetic events necessary for primary tumor growth
may also mediate metastatic behavior [3]. However, it is
difficult to reconcile how the same genetic alterations could
confer growth both in the breast microenvironment and in
other tissue microenvironments.
Recent work has begun to shed some light on the molecular
mechanisms that mediate tissue-specific metastasis and
reconcile this conceptual conflict. However, whether the
genes identified in these studies will elucidate the genetic
and, hopefully, predicative underlying mechanism for
metastasis, or rather represents an artifact of the model
systems employed for gene candidate discovery remains
uncertain.
Changing paradigms in breast cancer
metastasis
The widely accepted hypothesis first reported by Paget
suggests that breast cancer cells must express and utilize
specific migratory and adhesion molecules that cross-react
with those expressed in distant tissues in order to intravasate,
survive, and proliferate in that microenvironment. However,
when combined with the accepted mutation hypothesis, it is
difficult to conceive how breast cancer cells could be
selected during the process of primary tumor growth in the
breast stromal microenvironment also to express factors
specific for other tissue microenvironments.
There is an alternative explanation, which has received less
attention owing to the difficulty of studying the process. It
suggests that once cells extravasate out of the primary tissue
they genetically/epigenetically express migratory and
adhesion molecules as a consequence of genetic instability
and selection, which in turn facilitates their adhesion and
survival in tissues that express the reciprocal growth factor or
adhesion molecule [4].
However, recent studies have suggested a third possibility,
that single cells within a heterogeneous population already
express tissue-specific factors that would enable them to
grow preferentially in the lung, bone, or adrenal micro-
environments [5-7]. Although this work is intriguing and
demonstrates a novel mechanism of tissue-specific meta-
stasis, the model system utilized in those studies may not
reflect human breast cancer metastasis, or even tissue-
specific metastasis.
Model systems of human breast cancer
metastasis
Model systems for the study of human breast cancer
metastasis are currently limited. Several strategies have been
developed to study metastasis from the mouse mammary
gland. One involves the utilization of a sub-line of the invasive
human breast cancer cell line MDA-MB-231, which was
selected by serial in vivo passages for its ability to develop
bone metastases when injected through the tail vein of
immunocompromised mice [7]. This line, termed MDA-MB-
231Bo, along with MDA-MB-435 were the only two human
breast cancer cell lines utilized to model and unravel the
molecular mechanisms by which breast cancer metastasizes
from the orthotopic site. Because the parental MDA-MB-231
cell line was isolated from a pleural effusion and is not
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metastatic from the mammary gland, and the MDA-MB-435
cell line exhibits a melanoma rather than a breast cancer
phenotype, these cell lines may not accurately recapitulate
breast cancer metastasis and so caution is required when
translating the findings of such studies to humans.
Despite the caveats in the MDA-MB-231 cell line, this model
was employed to isolate clones that metastasize to the lung
and bone following injection of cells into the tail vein and left
cardiac ventricle of mice, respectively [5-7]. These studies
demonstrated the inherent variability in metastatic behavior
and gene expression within the MDA-MB-231 parental cell
line, and thus it was concluded that primary breast tumors are
also composed of a heterogeneous population of cells with
varying gene expression profiles and different metastatic
capabilities.
The method of injection of these breast cancer cell lines may
bias the metastatic phenotype. For example, cells injected
through the tail vein will follow the venous flow and
immediately encounter the lung capillary bed environment.
Similarly, cells injected through the left heart ventricle will
follow the arterial flow and deposit in organs encountered
along this blood flow route (e.g. bone). Because this model
system does not accurately reflect the metastatic process,
does this work reflect human breast cancer metastasis, or
even tissue-specific metastasis?
Possible genes that mediate metastasis
Given the clonal variability in breast cancer cells, microarray
analysis was performed on tissue-specific clonal lines to
examine what genes might mediate tissue selectivity during
metastasis. Surprisingly, the various clones isolated from the
MDA-MB-231 cell line exhibited distinct and differential in
vitro transcriptional profiles, suggesting a genetic/epigenetic
basis for the tissue-specific growth patterns of breast cancer.
Although some biologically interesting and novel genes were
identified by this process (e.g. ID1), several genes already
implicated in tissue-specific metastasis were identified (e.g.
MMP1,  IL11,  CXCR4,  OPN), thus shedding no light on
possible new candidates or mechanisms of action. Moreover,
the experimental procedure raises doubts regarding how
relevant these genes are in tissue-specific metastasis
because several of them are known to mediate metastasis in
a general manner and not necessarily specific to bone or lung
(CXCR4, MMP1) [8,9].
Concomitant overexpression of several of the parental
population genes identified by this approach conferred
tissue-specific growth, highlighting the fact that no one gene
was responsible for tissue-specific metastasis. Most
importantly, when utilizing small interfering RNA technology to
inhibit the expression of these genes in the clones, tissue-
specific metastasis was inhibited but not primary tumor
growth. This again suggested that a few critical genes could
confer this process. Based on these results, a specific gene
signature was obtained from several of these clones, and this
list of genes could be used to identify whether a patient-
derived primary tumor will metastasize to the lung. It was
surprising, however, that this approach was unable to predict
whether a breast cancer could metastasize to bone, given
that the majority of breast cancers metastasize to the
skeleton. It may be the case that although breast cancer
metastasis to bone may be inherent to all poor prognosis
breast cancers [3], lung metastasis might require an even
more defined molecular mechanism, which can be more
readily identified by microarray analysis.
The role of stroma in metastatic colonization
Although inhibiting specific genes may prove to be important
for preventing tissue-specific metastasis, the contribution of
stroma to tumor growth should not be ignored. Tissue stroma
has the ability to promote tumor growth [10]. For example,
the bone microenvironment is highly dynamic, and this in turn
is responsible for initiation and support of tumor growth.
Application of bisphosphonates, which suppress bone
turnover, can inhibit bone metastasis [11]. The importance of
stroma has also been demonstrated on the expression
pattern of MDA-MB-231 cells grown in vivo. The enzyme
activity profile of these cells grown in culture compared with
the same cells injected into the mammary fat pad of mice
revealed profound differences, indicating that there was a
stromal contribution to those grown in vivo [12]. The gene
expression of cells cultured in the absence of tissue stroma
could potentially change because of a loss of paracrine
signaling. Based on this, it does not seem possible to identify
accurately tissue-specific genes from microarray analysis
performed on cells grown in culture, as was previously done
[5-7]. Therefore, there remains much to be learned from
future experiments conducted to identify markers and targets
for metastasis, which take into account the contribution of the
microenvironment.
Conclusion
The ability to predict and prevent metastasis based on the
gene expression profile of a primary tumor would permit
targeted therapeutic intervention and increase patient
survival. However, the current models utilized to study breast
cancer metastasis leave questions unanswered and are
unable to identify accurately tissue-specific metastasis genes.
In the future, it will be helpful to develop more accurate
models that recapitulate breast cancer metastasis from an
orthotopic site, and employ these systems to identify and
elucidate the molecular and genetic mechanism that mediate
this complex process.
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